A newly published real world study exploring the use of ivermectin and mebendazole alongside cancer care is drawing significant attention among researchers, patients, and advocates of repurposed medicines.
Published in the journal Anticancer Research, the study followed 197 cancer patients with a variety of cancers including breast, prostate, colon, and lung cancer. Researchers investigated the effects of a compounded protocol using ivermectin and mebendazole, two long established medications with known safety histories and growing scientific interest for their potential anti cancer properties.
The study reported encouraging findings after approximately six months of treatment.
According to the published results, 84% of participants experienced some form of clinical benefit. This included patients whose cancer showed no evidence of disease, tumor shrinkage, or stable disease without progression.
Among the strongest reported outcomes:
• 33% showed no detectable evidence of disease
• 16% experienced measurable tumor reduction
• 36% maintained stable disease
• Only 16% experienced progression during the observation period
Researchers also noted that most participants tolerated the protocol well. Side effects were generally mild and primarily involved manageable digestive symptoms.
One particularly encouraging aspect of the study was patient adherence. Nearly 87% completed the initial course of therapy, suggesting the protocol was practical and tolerable for many individuals.
Importantly, many participants continued receiving conventional treatments such as chemotherapy, radiation, surgery, or hormonal therapy while using the ivermectin and mebendazole combination. This reflects growing interest in integrative approaches that combine standard oncology care with repurposed medicines being investigated for supportive or synergistic potential.
Scientists have become increasingly interested in repurposed drugs because they are often affordable, widely available, and already well understood from a safety perspective. Both ivermectin and mebendazole have demonstrated intriguing anti cancer activity in laboratory and animal studies over recent years.
Researchers studying these medicines have explored possible mechanisms involving:
• immune system modulation
• cancer stem cell signaling
• tumor metabolism disruption
• induction of apoptosis, or programmed cancer cell death
• interference with pathways linked to cancer growth and spread
The study involved collaboration between researchers and organizations including the McCullough Foundation, The Wellness Company, and epidemiologist Dr. Harvey Risch.
While the findings are promising, researchers acknowledge that larger randomized controlled trials are still needed to determine exactly how effective these therapies may be across different cancer types and stages.
Even so, the publication represents an important milestone in the growing field of drug repurposing and integrative oncology. Many patients facing difficult diagnoses are eager to see more research into low cost therapies that could potentially complement existing cancer treatments.
The study adds to a growing body of discussion surrounding innovative approaches to cancer care and highlights the importance of continuing scientific investigation into therapies that may improve outcomes, accessibility, and quality of life for patients worldwide.
As research continues, many in the medical and patient communities will be watching closely to see whether future controlled trials confirm the encouraging trends observed in this early real world data.
Written by Maryjayne Aria Author of immune health, terrain and GcMaf
Feel free to see my blog on www.maryjaynearia.com
